Submission of Audited Financial Results of the Company for the quarter and financial year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenotech Laboratories reported standalone revenue from operations of Rs 3,897.57 lakhs for FY25, up about 6% from Rs 3,676.15 lakhs in FY24. However, profit after tax fell sharply to Rs 561.29 lakhs from Rs 829.87 lakhs, a drop of roughly 32%, mainly because total expenses rose over 16% and the tax bill jumped from Rs 284.27 lakhs to Rs 507.90 lakhs (including current and prior period tax). The company booked a one-time gain of Rs 192.32 lakhs as an exceptional item from the DGFT Amnesty Scheme settling export obligation defaults on EPCG licenses. Cash and cash equivalents jumped to Rs 2,657.51 lakhs from Rs 181.57 lakhs, largely on release of margin money deposits. Statutory auditor PKF Sridhar & Santhanam LLP issued an unmodified opinion.
Topline growth is modest, but earnings quality is weak: operating margins compressed sharply and tax expenses surged, pulling down PAT by a third despite the exceptional gain. The fattened cash balance is a positive, but underlying profitability has clearly deteriorated and may weigh on the stock in the near term.